FDA Expands Clinical Trial Eligibility for Cancer Patients

The FDA finalized three guidance documents to broaden eligibility criteria for oncology clinical trials, aiming to expand patient access by addressing restrictive measures like performance status and washout periods. These changes seek to include more real-world patients, particularly older individuals with complex medical histories, though adoption by sponsors and research organisations is necessary for impact.

This Wire brief sits within Fusion42's coverage of Biotech.